Laurent Pessaint
Overview
Explore the profile of Laurent Pessaint including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
5019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Misasi J, Wei R, Wang L, Pegu A, Wei C, Oloniniyi O, et al.
Sci Transl Med
. 2024 Oct;
16(768):eado9026.
PMID: 39383243
Despite effective countermeasures, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persists worldwide because of its ability to diversify and evade human immunity. This evasion stems from amino acid substitutions, particularly...
2.
Gagne M, Flynn B, Andrew S, Marquez J, Flebbe D, Mychalowych A, et al.
Nat Immunol
. 2024 Sep;
25(10):1913-1927.
PMID: 39227514
A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.16 challenge...
3.
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Gagne M, Flynn B, Honeycutt C, Flebbe D, Andrew S, Provost S, et al.
Nat Commun
. 2024 Aug;
15(1):6894.
PMID: 39134521
SARS-CoV-2 has the capacity to evolve mutations that escape vaccine- and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on...
4.
McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann N, et al.
Nature
. 2023 Dec;
626(7998):385-391.
PMID: 38096903
A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants, although they still provide protection against severe disease. Enhanced mucosal immunity may...
5.
Moliva J, Andrew S, Flynn B, Wagner D, Foulds K, Gagne M, et al.
bioRxiv
. 2023 Dec;
PMID: 38076895
SARS-CoV-2 continues to pose a global threat, and current vaccines, while effective against severe illness, fall short in preventing transmission. To address this challenge, there's a need for vaccines that...
6.
Gagne M, Flynn B, Andrew S, Flebbe D, Mychalowych A, Lamb E, et al.
bioRxiv
. 2023 Nov;
PMID: 37986823
Graphical Abstract:
7.
Aid M, Sciacca M, McMahan K, Hope D, Liu J, Jacob-Dolan C, et al.
Cell
. 2023 Sep;
186(21):4652-4661.e13.
PMID: 37734373
The mpox outbreak of 2022-2023 involved rapid global spread in men who have sex with men. We infected 18 rhesus macaques with mpox by the intravenous, intradermal, and intrarectal routes...
8.
Gagne M, Flynn B, Honeycutt C, Flebbe D, Andrew S, Provost S, et al.
bioRxiv
. 2023 Jul;
PMID: 37503026
SARS-CoV-2 has the capacity to evolve mutations to escape vaccine-and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the...
9.
Yu J, Thomas P, Sciacca M, Wu C, Liu J, He X, et al.
Cell Rep Med
. 2023 Apr;
4(4):101018.
PMID: 37023746
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5...
10.
Misasi J, Wei R, Wang L, Pegu A, Wei C, Oloniniyi O, et al.
bioRxiv
. 2022 Aug;
PMID: 35982683
Despite effective countermeasures, SARS-CoV-2 persists worldwide due to its ability to diversify and evade human immunity. This evasion stems from amino-acid substitutions, particularly in the receptor-binding domain of the spike,...